
Top Stocks
Top Obesity Treatment Stocks: Our 3 Picks for August 2026
A countdown of three obesity-drug stocks spanning a digital care platform and global pharmaceutical manufacturers, with detailed fundamentals and momentum.
May 30, 20268 MIN
Every article, report, and earnings note where LLY appears.

A countdown of three obesity-drug stocks spanning a digital care platform and global pharmaceutical manufacturers, with detailed fundamentals and momentum.

Eli Lilly and Company (LLY) rises after a strong Q1 2026 beat, a higher full-year outlook, and early launch momentum for its oral GLP-1 obesity pill Foundayo. The rally reflects continued strength in Mounjaro and Zepbound, reinforcing Lilly’s status as a leading growth story in healthcare.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate LLY ReportCancel anytime